Plant Name: Radula voluta
Taxonomic Information:
Plant ID: NPO28247
Plant Latin Name: Radula voluta
Taxonomy Genus: Radula
Taxonomy Family: Radulaceae
Plant External Links:
NCBI TaxonomyDB:
399160
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; | |
| BCHE; GAA; ACHE; | |
| HIF1A; | |
| RAD52; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.745E-09 | 2.989E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.014E-08 | 2.188E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.678E-07 | 8.899E-04 | BCHE, CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.418E-07 | 8.899E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.948E-07 | 8.899E-04 | ACHE, BCHE |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.842E-07 | 1.750E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.768E-06 | 2.961E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.924E-06 | 2.993E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.617E-06 | 7.644E-03 | ACHE, BCHE, DRD1 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.940E-05 | 1.920E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.292E-05 | 2.170E-02 | SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 4.489E-05 | 3.508E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.357E-06 | 1.394E-04 | CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.538E-06 | 1.394E-04 | CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 1.366E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.470E-04 | 4.135E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.613E-04 | 4.154E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.917E-04 | 5.499E-03 | CYP1A2, CYP3A4 |
| 09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 3.843E-03 | 1.777E-02 | SMN2, SMN1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.638E-02 | 6.061E-02 | GAA |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03440 | Homologous recombination | 1.584E-02 | 6.061E-02 | RAD52 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.747E-03 | 1.452E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
